Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immutep Limited stock logo
IMMP
Immutep
$1.70
$1.95
$1.65
$3.34
$247.45M2.3476,054 shs42,346 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.73
-1.0%
$26.28
$24.48
$31.54
$145.79B0.6140.13 million shs37.26 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immutep Limited stock logo
IMMP
Immutep
-2.86%-5.56%-15.84%-27.97%-33.33%
Pfizer Inc. stock logo
PFE
Pfizer
-2.36%+1.10%+0.94%+2.96%-8.35%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Immutep Limited stock logo
IMMP
Immutep
1.8134 of 5 stars
3.52.00.00.03.60.00.0
Pfizer Inc. stock logo
PFE
Pfizer
4.8876 of 5 stars
2.33.04.24.22.83.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immutep Limited stock logo
IMMP
Immutep
3.00
Buy$8.50400.00% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.50
Moderate Buy$31.9224.09% Upside

Current Analyst Ratings Breakdown

Latest IMMP and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
2/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
1/28/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $29.00
1/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$31.00 ➝ $29.00
12/18/2024
Pfizer Inc. stock logo
PFE
Pfizer
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$36.00 ➝ $32.00
(Data available from 3/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immutep Limited stock logo
IMMP
Immutep
$5.14M48.14N/AN/A$1.05 per share1.62
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.29$4.03 per share6.38$15.81 per share1.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immutep Limited stock logo
IMMP
Immutep
-$28.01MN/A0.00N/AN/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4118.248.490.6412.62%19.47%8.09%4/29/2025 (Estimated)

Latest IMMP and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Immutep Limited stock logo
IMMP
Immutep
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.69%+2.50%121.99%16 Years

Latest IMMP and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/12/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.78%1/24/20251/24/20253/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immutep Limited stock logo
IMMP
Immutep
0.01
18.25
18.25
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
Immutep Limited stock logo
IMMP
Immutep
2.32%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Immutep Limited stock logo
IMMP
Immutep
3.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immutep Limited stock logo
IMMP
Immutep
2,021145.56 million141.09 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.67 billion5.66 billionOptionable

Recent News About These Companies

Guggenheim Reaffirms Their Buy Rating on Pfizer (PFE)
Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Shares Down 1.5% - Here's Why
Pfizer Inc. stock logo
Guggenheim Reiterates "Buy" Rating for Pfizer (NYSE:PFE)
Pfizer Inc. stock logo
Pfizer Inc. (NYSE:PFE) Shares Sold by AGF Management Ltd.
Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Trading Down 1.8% - What's Next?
Arvinas, Pfizer Report Positive Phase 3 VERITAC-2 Results
Pfizer: Undervalued Safe Haven In Risk-Off Market​
Pfizer: Undervalued Safe Haven In Risk-Off Market​

New MarketBeat Followers Over Time

Media Sentiment Over Time

Immutep stock logo

Immutep NASDAQ:IMMP

$1.70 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.74 +0.04 (+2.59%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Pfizer stock logo

Pfizer NYSE:PFE

$25.72 -0.27 (-1.02%)
Closing price 03:59 PM Eastern
Extended Trading
$25.76 +0.03 (+0.12%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.